구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isotretinoin |
Overview Company | Multan Medical And Dental College |
Overview Modality | CGT |
Overview Target | Neuroblastoma |
Overview Indication | Neuroblastoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | and has demonstrated differentiation-inducing activity in vitro and in limited clinical reports |
MoA Biomarker | biomarkers, such as the micronucleus assay, the comet assay, and oxidative DNA damage markers, were included |
PK/PD Half-life | 90 days |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.. Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence. We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, ma… |
Clinical Safety signal | Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.. Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence. We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, ma… |
Clinical Selected reported efficacy | 50% |
Clinical Result source | ClinicalTrials.gov NCT01857934 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01857934 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Isotretinoin |
Overview Company | Multan Medical And Dental College |
Overview Modality | CGT |
Overview Target | Neuroblastoma |
Overview Indication | Neuroblastoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | and has demonstrated differentiation-inducing activity in vitro and in limited clinical reports |
MoA Biomarker | biomarkers, such as the micronucleus assay, the comet assay, and oxidative DNA damage markers, were included |
PK/PD Half-life | 90 days |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.. Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence. We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, ma… |
Clinical Safety signal | Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.. Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence. We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, ma… |
Clinical Selected reported efficacy | 50% |
Clinical Result source | ClinicalTrials.gov NCT01857934 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01857934 |
추천 비교
추천 비교